<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176913</url>
  </required_header>
  <id_info>
    <org_study_id>BM2L201904</org_study_id>
    <secondary_id>BM2L201904</secondary_id>
    <nct_id>NCT04176913</nct_id>
    <nct_alias>NCT04994587</nct_alias>
  </id_info>
  <brief_title>Study of LUCAR-20S in Patients With R/R NHL</brief_title>
  <official_title>A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of LUCAR-20S in Patients With Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC west district; Beijing Boren Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, single arm Phase I study to evaluate the safety, tolerability, and&#xD;
      pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large&#xD;
      B-cell, follicular, mantle cell and small lymphocytic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open, dose escalation/dose regimen finding study to assess the safety and&#xD;
      pharmacokinetics of donor-derived CD20-directed CAR-T cells administered with&#xD;
      lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been&#xD;
      diagnosed with relapsed or refractory CD20 positive diffuse large B-cell lymphoma, follicular&#xD;
      lymphoma, mantle cell lymphoma or small lymphocytic lymphoma. The allo-CAR-T cells will be&#xD;
      infused in single-dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">January 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>30 days post infusion</time_frame>
    <description>DLT assessed by NCI-CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>90 days post infusion</time_frame>
    <description>Incidence and severity of adverse events as assessed by NCI-CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Pharmacokinetics in blood</measure>
    <time_frame>through study completion, 2 years after infusion of the last subject</time_frame>
    <description>PK CAR positive T cells in peripheral blood, PK CAR transgene levels in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Pharmacokinetics in bone marrow</measure>
    <time_frame>through study completion, 2 years after infusion of the last subject</time_frame>
    <description>PK CAR positive T cells in bone marrow, PK CAR transgene levels in bone marrow</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase II dose (RP2D)</measure>
    <time_frame>30 days post infusion</time_frame>
    <description>RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) after administration</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>Antitumor efficacy by 2014 Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) after administration</measure>
    <time_frame>3 months post infusion</time_frame>
    <description>Antitumor efficacy by 2014 Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR) after administration</measure>
    <time_frame>through study completion, 2 years after infusion of the last subject</time_frame>
    <description>Antitumor efficacy by 2014 Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival (PFS) after administration</measure>
    <time_frame>through study completion, 2 years after infusion of the last subject</time_frame>
    <description>Antitumor efficacy by 2014 Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) after administration</measure>
    <time_frame>through study completion, 2 years after infusion of the last subject</time_frame>
    <description>Antitumor efficacy by 2014 Lugano criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Anti-CD20 Allogeneic CAR-T Cell Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUCAR-20S CAR-T cells</intervention_name>
    <description>An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma</description>
    <arm_group_label>Anti-CD20 Allogeneic CAR-T Cell Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form (ICF)&#xD;
&#xD;
          2. Age 18 Years to 75 Years&#xD;
&#xD;
          3. Pathological diagnosis of refractory/relapsed CD20+ non-Hodgkin's lymphoma (one of the&#xD;
             following):&#xD;
&#xD;
               1. Diffuse large B-cell lymphoma (DLBCL)&#xD;
&#xD;
               2. Follicular lymphoma (FL)&#xD;
&#xD;
               3. Mantle cell lymphoma (MCL)&#xD;
&#xD;
               4. Small lymphocytic lymphoma (SLL)&#xD;
&#xD;
          4. Measurable disease as defined by 2014 Lugano criteria at Screening&#xD;
&#xD;
          5. Refractory/relapsed disease after standard-of- care treatment as following (Undergone&#xD;
             at least 2 complete cycle of therapy for each line, unless PD been documented as the&#xD;
             best response to the regimen) and not eligible or appropriate for HSCT (Auto/allo).&#xD;
             Subject must have documented evidence of progressive disease on or within 12 months of&#xD;
             their last regimen.&#xD;
&#xD;
               1. DLBCL: Refractory/relapsed after at least 1 prior line of therapy, must have been&#xD;
                  treated with anti-CD20 monoclonal antibody&#xD;
&#xD;
               2. FL: Refractory/relapsed after at least 2 prior lines of therapy, must have been&#xD;
                  treated with anti-CD20 monoclonal antibody&#xD;
&#xD;
               3. MCL: Refractory/relapsed after at least 2 prior lines of therapy&#xD;
&#xD;
               4. SLL: Refractory/relapsed after at least 2 prior lines of therapy&#xD;
&#xD;
          6. Laboratory criteria at Screening&#xD;
&#xD;
             ① Blood routine: NE≥1.0×109/L；HGB≥8g/dL；PLT≥50×109/L&#xD;
&#xD;
             ② Blood biochemical parameters:&#xD;
&#xD;
               1. Total bilirubin ≤ 1.5 times of the normal upper limit (ULN)&#xD;
&#xD;
               2. Aspartate and alanine aminotransferases (AST, ALT) ≤ 3 times ULN (in the presence&#xD;
                  of liver metastasis, ULN 5 times)&#xD;
&#xD;
               3. Estimated glomerular filtration rate (eGFR) &gt; 60mL/min&#xD;
&#xD;
          7. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any malignancy besides the NHL categories under study, exceptions include&#xD;
&#xD;
               1. Any other malignancy curatively treated and disease-free for at least 2 years&#xD;
                  prior to enrollment&#xD;
&#xD;
               2. History of non-melanoma skin cancer with sufficient treatment and currently no&#xD;
                  evidence of recurrence&#xD;
&#xD;
          2. Prior treatment with an allogeneic stem cell transplant&#xD;
&#xD;
          3. Prior treatment with genetic therapy&#xD;
&#xD;
          4. Prior treatment with chimeric antigen receptor T (cells) CAR-T therapy directed at&#xD;
             CD20 target&#xD;
&#xD;
          5. Those who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis&#xD;
             B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C&#xD;
             virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab)&#xD;
&#xD;
          6. Prior antitumor therapy with insufficient washout period&#xD;
&#xD;
               1. Targeted therapy, epigenetic therapy, experimental drug therapy or experimental&#xD;
                  invasive treatment with medical apparatus and instruments 14 days or five&#xD;
                  half-lives, whichever is shorter before lymphodepletion&#xD;
&#xD;
               2. Use of monoclonal antibodies 21 days prior to lymphodepletion&#xD;
&#xD;
               3. Chemotherapy within 14 days prior to lymphodepletion&#xD;
&#xD;
               4. Radiotherapy within 14 days prior to lymphodepletion&#xD;
&#xD;
               5. Participated in other clinical trials within 30 days prior to lymphodepletion&#xD;
&#xD;
          7. With central nervous system involvement&#xD;
&#xD;
          8. Women in pregnancy or lactation&#xD;
&#xD;
          9. Being fertile and unable to use effective conception during treatment and 100 days&#xD;
             after CAR-T infusion&#xD;
&#xD;
         10. Active autoimmune disease or history of autoimmune disease within 3 years&#xD;
&#xD;
         11. With obvious hemorrhagic tendency such as gastrointestinal hemorrhage, coagulation&#xD;
             disorders and hypersplenism&#xD;
&#xD;
         12. The following cardiac conditions&#xD;
&#xD;
               1. New York Heart Association (NYHA) stage III or IV congestive heart failure&#xD;
&#xD;
               2. Left ventricular ejection fraction (LVEF) less than (&lt;)45%&#xD;
&#xD;
               3. Uncontrolled cardiac arrhythmia post-medication&#xD;
&#xD;
               4. With a history of myocardial infraction or unstable angina pectoris within the&#xD;
                  past 6 months&#xD;
&#xD;
               5. Constrictive pericarditis&#xD;
&#xD;
               6. Cardiomyopathy&#xD;
&#xD;
         13. Pulse oximetry of &lt;96% on room air&#xD;
&#xD;
         14. Active or uncontrolled infection requiring parenteral antibiotics, or any evidence of&#xD;
             severe active viral/bacterial infection or uncontrolled systemic fungal infection&#xD;
&#xD;
         15. Uncontrolled diabetes mellitus, defined as fast serum glucose &gt; 1.5 times ULN&#xD;
&#xD;
         16. Concurrent use of corticosteroids or other immunosuppressant medications for chronic&#xD;
             disease&#xD;
&#xD;
         17. Concurrent use of hematopoietic growth factor&#xD;
&#xD;
         18. Stroke or seizure within 6 months of signing ICF&#xD;
&#xD;
         19. Have received any live, attenuated vaccine within 4 weeks prior to lymphodepletion&#xD;
&#xD;
         20. Have underwent major surgical operation within 2 weeks prior to lymphodepletion, or&#xD;
             anticipate to undergo a major surgical operation during the study process or within 2&#xD;
             weeks posterior to study treatment(with the exception of anticipated local anesthesia&#xD;
             surgery)&#xD;
&#xD;
         21. Known life threatening allergies, hypersensitivity, or intolerance to LUCAR-20S CAR-T&#xD;
             cells or its excipients, including dimethyl sulfoxide (DMSO)&#xD;
&#xD;
         22. Presence of any condition that, in the opinion of the investigator, would prohibit the&#xD;
             patient from undergoing treatment under this protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, PhD&amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaiyang Ding, PhD&amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anhui Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kai Hu, PhD&amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Boren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Wang, PhD&amp; MD</last_name>
    <phone>+8668306034</phone>
    <email>lilyw7878@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department，The First Affiliated Hospital of USTC west district</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaiyang Ding, PhD&amp; MD</last_name>
      <phone>+86055165897860</phone>
      <email>dingkaiy@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematological Department, People's Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Xu, Ph.D.</last_name>
      <phone>+86-2568302182</phone>
      <email>xuwei10000@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematological Department，Beijing Boren Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Hu, PhD&amp; MD</last_name>
      <phone>+8615010390336</phone>
      <email>xiaohu7079@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Chief Physician of hematology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

